SB-431542
![]() | |
Names | |
---|---|
Preferred IUPAC name 4-[4-(2H-1,3-Benzodioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl]benzamide | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEBI |
|
ChEMBL |
|
ChemSpider |
|
IUPHAR/BPS |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C22H16N4O3 |
Molar mass | 384.395 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references |
SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7.[1] However, it is not an inhibitor of anaplastic lymphoma kinase (which are commonly known as ALK inhibitors).
In-vitro studies
While SB-431542 has not proved directly useful for any clinical application, it is used for several applications in molecular biology. It suppresses the TGF-beta-induced proliferation of osteosarcoma cells in humans.[1] SB431542 can also be used in combination with LDN193189, CHIR99021 and DAPT to transform astrocytes into neurons.[2] It is also commonly used for immunological studies, for instance as a TGF-β inhibitor to facilitate the generation of dendritic cells from peripheral blood monocytes. [3]
References
- ^ a b Laping, NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA (2002). "Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542". Molecular Pharmacology. 62 (1): 58–64. doi:10.1124/mol.62.1.58. PMID 12065755.
- ^ Yin, Jiu-Chao; Zhang, Lei; Ma, Ning-Xin; Wang, Yue; Lee, Grace; Hou, Xiao-Yi; Lei, Zhuo-Fan; Zhang, Feng-Yu; Dong, Feng-Ping; Wu, Gang-Yi; Chen, Gong (2019). "Chemical Conversion of Human Fetal Astrocytes into Neurons through Modulation of Multiple Signaling Pathways". Stem Cell Reports. 12 (3): 488–501. doi:10.1016/j.stemcr.2019.01.003. PMC 6409415. PMID 30745031.
- ^ Mondanelli G; Bianchi R; Pallotta MT; Orabona C; Albini E; Iacono A; Belladonna ML; Vacca C; Fallarino F; Macchiarulo A; Ugel S; Bronte V; Gevi F; Zolla L; Verhaar A; Peppelenbosch M; Mazza EMC; Bicciato S; Laouar Y; Santambrogio L; Puccetti P; Volpi C; Grohmann U (2017). "A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells". Immunity. 42 (2): 233–244. doi:10.1016/j.immuni.2017.01.005. PMC 5337620. PMID 30745031.
- v
- t
- e
ALK1 (ACVRL1) | |
---|---|
ALK2 (ACVR1A) | |
ALK3 (BMPR1A) | |
ALK4 (ACVR1B) | |
ALK5 (TGFβR1) |
|
ALK6 (BMPR1B) | |
ALK7 (ACVR1C) |
TGFβR2 |
|
---|---|
BMPR2 | |
ACVR2A (ACVR2) | |
ACVR2B | |
AMHR2 (AMHR) |
|
TGFβR3 (β-glycan) |
---|
- Endogenous antagonists/inhibitors: BAMBI
- Cerberus (CER1)
- Chordin
- DAN (PARN)
- Decorin
- Follistatin
- Gremlin (Drm)
- LTBP1
- Noggin
- TGIF
- Thrombospondin 1 (THBS1)
- Tomoregulin 1
- Antibodies: Stamulumab (against myostatin)
- TRC105 (against endoglin)
- Others: Endoglin